Cedar Valley Digestive Health Center
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
Randomized, double-blind, placebo controlled trial of tenapanor vs. placebo for treating synucleinopathy-associated constipation in Parkinson\'s disease.
Inclusion Criteria 1. Age 50-89 years. 2. Diagnosis of PD within Hoehn and Yahr stages 1-3, confirmed by a neurologist per International Parkinson and Movement Disorder Society criteria. 3. Average weekly stool frequency of ≤5 spontaneous bowel movements (SBMs) and ≤2 complete spontaneous bowel movements (CSBMs) over the past 6 months. These criteria will be verified during a 2-week screening period. 4. Stool consistency ≤3 on the Bristol Stool Form Scale (BSFS). This criterion will be verified during a 2-week screening period. 5. Agreement to use contraception, if applicable. Exclusion Crit…
Inhibitor of NHE3
Placebo drug
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.